M Fava

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Folate, vitamin B12, and homocysteine in major depressive disorder
    M Fava
    Depression Clinical and Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA
    Am J Psychiatry 154:426-8. 1997
  2. ncbi Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 154:1760-2. 1997
  3. ncbi Hypochondriacal concerns in depressed outpatients
    C Demopulos
    Depression Research Program, Massachusetts General Hospital, Boston 02114, USA
    Psychosom Med 58:314-20. 1996
  4. ncbi Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression
    M Fava
    Depression Clinical and Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, WAC 812, 15 Parkman Street, 02114, Boston, MA, USA
    J Affect Disord 59:119-26. 2000
  5. ncbi Timing of onset of antidepressant response with fluoxetine treatment
    A A Nierenberg
    Depression and Clinical Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 157:1423-8. 2000
  6. ncbi Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression
    D Mischoulon
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman St, WAC 812, Boston, MA 02114, USA
    J Psychosom Res 49:183-7. 2000
  7. ncbi Outcome definitions and predictors in depression
    J Tedlow
    Depression Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychother Psychosom 67:266-70. 1998
  8. doi Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report
    A A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychol Med 40:41-50. 2010
  9. ncbi T3 blood levels and treatment outcome in depression
    D V Iosifescu
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Int J Psychiatry Med 31:367-73. 2001
  10. ncbi Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 62:413-20. 2001

Collaborators

Detail Information

Publications41

  1. ncbi Folate, vitamin B12, and homocysteine in major depressive disorder
    M Fava
    Depression Clinical and Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA
    Am J Psychiatry 154:426-8. 1997
    ..The authors examined the relationships between levels of three metabolites (folate, vitamin B12, and homocysteine) and both depressive subtype and response to fluoxetine treatment in depressed patients...
  2. ncbi Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 154:1760-2. 1997
    ..The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration...
  3. ncbi Hypochondriacal concerns in depressed outpatients
    C Demopulos
    Depression Research Program, Massachusetts General Hospital, Boston 02114, USA
    Psychosom Med 58:314-20. 1996
    ....
  4. ncbi Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression
    M Fava
    Depression Clinical and Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, WAC 812, 15 Parkman Street, 02114, Boston, MA, USA
    J Affect Disord 59:119-26. 2000
    ..For this reason, using head-to-head acute treatment comparison, we compared efficacy and tolerability of fluoxetine, sertraline, and paroxetine among depressed patients with high levels of anxiety...
  5. ncbi Timing of onset of antidepressant response with fluoxetine treatment
    A A Nierenberg
    Depression and Clinical Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 157:1423-8. 2000
    ..The purpose of this study was to assess the time until onset of antidepressant response with fluoxetine treatment...
  6. ncbi Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression
    D Mischoulon
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman St, WAC 812, Boston, MA 02114, USA
    J Psychosom Res 49:183-7. 2000
    ..We wished to determine whether anemia or macrocytosis predict hypofolatemia, low B12, or refractoriness to antidepressants...
  7. ncbi Outcome definitions and predictors in depression
    J Tedlow
    Depression Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychother Psychosom 67:266-70. 1998
    ..We therefore wanted to investigate possible relationships between baseline severity of depression and anxiety, and different definitions of outcome among outpatients with major depressive disorder undergoing antidepressant treatment...
  8. doi Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report
    A A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychol Med 40:41-50. 2010
    ..We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial...
  9. ncbi T3 blood levels and treatment outcome in depression
    D V Iosifescu
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Int J Psychiatry Med 31:367-73. 2001
    ..CONCLUSION: Abnormal T3-RU levels are rather uncommon in outpatient depression and do not correlate with the response to antidepressant treatment or lack thereof...
  10. ncbi Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 62:413-20. 2001
    ..To evaluate the efficacy and safety of mirtazapine in depressed outpatients who have shown nonresponse or intolerance to selective serotonin reuptake inhibitor (SSRI) therapy...
  11. ncbi Course and treatment of atypical depression
    A A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 59:5-9. 1998
    ..A review and critique of the relevant literature on atypical depression will be presented...
  12. ncbi Treatment resistant depression and axis I co-morbidity
    T Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Psychol Med 31:1223-9. 2001
    ..In fact, the only statistical difference showed non-TRD patients with higher co-morbidity rates...
  13. ncbi Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day
    R H Perlis
    Depression Clinical and Research Program, Massachusetts General Hospital, WACC 812, 15 Parkman Street, Boston, MA 02114, USA
    Acta Psychiatr Scand 108:432-8. 2003
    ..Factors moderating response to these next-step interventions are not well-studied...
  14. pmc The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication
    M Fava
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Mol Psychiatry 15:856-67. 2010
    ..Further investigation is warranted of distinct family aggregation, risk factors and treatment response. Consideration should also be given to including irritability as a nondiagnostic symptom of adult MDD in DSM-V and ICD-11...
  15. ncbi New approaches to the treatment of refractory depression
    M Fava
    Department of Psychiatry, Harvard Medical School, Boston, Mass, USA
    J Clin Psychiatry 61:26-32. 2000
    ..The review of treatment options for refractory depression that follows will outline the advantages, disadvantages, and level of support for a number of new treatment strategies...
  16. ncbi Tryptophan depletion in SSRI-recovered depressed outpatients
    M K Spillmann
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychopharmacology (Berl) 155:123-7. 2001
    ..No other predicting or mediating factors were identified, although the variable "history of response pattern to medication" deserves further study...
  17. ncbi Management of major depression in the primary care setting
    D Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Psychother Psychosom 70:103-7. 2001
    ..We wished to determine how PCPs in a community clinic setting initially manage patients newly diagnosed with major depression...
  18. ncbi Fenfluramine challenge in unipolar depression with and without anger attacks
    M Fava
    Depression Clinical and Research Program, WACC 812, Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114, USA
    Psychiatry Res 94:9-18. 2000
    ....
  19. ncbi Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment
    M Fava
    Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 61:863-7. 2000
    ..Also unknown is whether different agents have differential effects. To examine these questions, we assessed weight changes in patients randomly assigned to long-term treatment with fluoxetine, sertraline, or paroxetine...
  20. pmc Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder
    R H Perlis
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Acta Psychiatr Scand 119:282-9. 2009
    ..We examined clinical correlates of irritability in a confirmatory cohort of Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study participants with major depressive disorder (MDD)...
  21. ncbi Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine
    T Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Psychol Med 34:555-61. 2004
    ..The goal of this study was to examine whether CBT would help maintain attributional style changes experienced by patients during acute phase fluoxetine treatment...
  22. ncbi Use of the five-factory inventory in characterizing patients with major depressive disorder
    T Petersen
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Compr Psychiatry 42:488-93. 2001
    ..Future studies should examine how such personality factors affect response to treatment and course of illness...
  23. ncbi Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians
    D Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Can J Psychiatry 45:476-81. 2000
    ..To examine treatment practices in cases where selective serotonin reuptake inhibitors (SSRIs) are ineffective...
  24. doi Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder
    D V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    Acta Psychiatr Scand 117:271-6. 2008
    ..We investigated frontal quantitative EEG (QEEG) as predictor of changes in suicidal ideation (SI) during SSRI treatment in major depressive disorder (MDD)...
  25. ncbi Augmentation and combination strategies in treatment-resistant depression
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 62:4-11. 2001
    ..Further studies are clearly needed to evaluate the comparative efficacy and tolerability of these different approaches in treatment-resistant depressions...
  26. ncbi The anxiety sensitivity index: item analysis and suggestions for refinement
    M A Blais
    Inpatient Psychiatry Service, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Pers Assess 77:272-94. 2001
    ..The 11-item ASI appears to tap 2 primary aspects of anxiety sensitivity: fears of somatic sensations of anxiety and fears of loss of mental control. Suggestions for further development of the ASI are offered...
  27. pmc Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model
    R H Perlis
    Depression Clinic and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Psychol Med 42:41-50. 2012
    ..Electronic medical records (EMR) provide a unique opportunity for efficient, large-scale clinical investigation in psychiatry. However, such studies will require development of tools to define treatment outcome...
  28. ncbi The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD)
    A H Farabaugh
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA WAC 812, USA
    Acta Psychiatr Scand 110:465-70. 2004
    ....
  29. ncbi Additional findings on the association between anxiety sensitivity and hypochondriacal concerns: examination of patients with major depression
    M W Otto
    Cognitive Behavior Therapy Program, Massachusetts General Hospital, Boston 02114, USA
    J Anxiety Disord 12:225-32. 1998
    ..Findings are discussed in relation to the role of catastrophic interpretations of somatic symptoms in depression, panic disorder, and hypochondriasis...
  30. ncbi An open trial of oral sildenafilin antidepressant-induced sexual dysfunction
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass 02114, USA
    Psychother Psychosom 67:328-31. 1998
    ..The goal of our study was to evaluate its efficacy in a small sample of outpatients with antidepressant-induced sexual dysfunction...
  31. ncbi Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review
    J Sporn
    Department of Psychiatry, Massachusetts General Hospital, USA
    Ann Clin Psychiatry 12:137-40. 2000
    ..To assess the effectiveness and safety of pramipexole as an adjunctive medication in refractory bipolar and unipolar depression in a naturalistic setting...
  32. ncbi Personality disorders and depression
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Psychol Med 32:1049-57. 2002
    ....
  33. pmc A detailed examination of cytokine abnormalities in Major Depressive Disorder
    N M Simon
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 18:230-3. 2008
    ..These data support a generalized chronic inflammatory state in MDD, and implicate additional cytokines and chemokines previously linked to cardiovascular disease...
  34. doi A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    G I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Department of Psychiatry, Boston, MA 02114, USA
    J Psychopharmacol 22:843-8. 2008
    ..8; 95% CI: 1.3-2.4; P < 0.0001) during the course of treatment. These results suggest that mirtazapine and the SSRIs differ with respect to their side-effect profile but not their overall efficacy in the treatment of MDD...
  35. pmc Psychosocial stressors and the prognosis of major depression: a test of Axis IV
    S E Gilman
    Department of Society, Human Development, and Health, Harvard School of Public Health, Boston, MA, USA
    Psychol Med 43:303-16. 2013
    ..Axis IV is for reporting 'psychosocial and environmental problems that may affect the diagnosis, treatment and prognosis of mental disorders'. No studies have examined the prognostic value of Axis IV in DSM-IV...
  36. ncbi Risk of suicidality in depression with serotonergic antidepressants
    J D Matthews
    Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
    Ann Clin Psychiatry 12:43-50. 2000
    ..Prescribing inadequate doses of antidepressants is therefore a source of overlooked risk...
  37. ncbi Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine
    P Cassano
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, U S A
    Arch Womens Ment Health 7:167-71. 2004
    ..To examine sex- and age-related differences of treatment outcome in a cohort of outpatients with major depressive disorder (MDD), with and without comorbid anxiety, treated with fluoxetine...
  38. ncbi Screening for major depression in Asian-Americans: a comparison of the Beck and the Chinese Depression Inventory
    A Yeung
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Acta Psychiatr Scand 105:252-7. 2002
    ..This study compares the effectiveness of the Chinese version of the Beck Depression Inventory (CBDI) and the Chinese Depression Inventory (CDI) in screening for depression among Chinese Americans...
  39. ncbi Severe depression: is there a best approach?
    S B Sonawalla
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    CNS Drugs 15:765-76. 2001
    ..g. renal, cardiac or hepatic disease)...
  40. ncbi Proposed DSM-5 mixed features are associated with greater likelihood of remission in out-patients with major depressive disorder
    R H Perlis
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Psychol Med 44:1361-7. 2014
    ..Draft DSM-5 criteria for a mixed major depressive episode have been proposed, but their predictive validity has not yet been established. We hypothesized that such symptoms would be associated with poorer antidepressant treatment outcomes...
  41. ncbi BDNF, relative preference, and reward circuitry responses to emotional communication
    G P Gasic
    Motivation and Emotion Neuroscience Collaboration MENC, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Med Genet B Neuropsychiatr Genet 150:762-81. 2009
    ..This study demonstrates that functional allelic variation in BDNF modulates human brain circuits processing reward/aversion information and relative preference transactions...